Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Current Leases (2022 - 2025)

Caribou Biosciences (CRBU) has disclosed Current Leases for 4 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Current Leases fell 15.78% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, down 15.78% year-over-year, with the annual reading at $1.2 million for FY2025, 15.78% down from the prior year.
  • Current Leases for Q4 2025 was $1.2 million at Caribou Biosciences, down from $2.7 million in the prior quarter.
  • The five-year high for Current Leases was $2.7 million in Q3 2025, with the low at $825000.0 in Q1 2022.
  • Average Current Leases over 4 years is $1.3 million, with a median of $1.2 million recorded in 2023.
  • Peak annual rise in Current Leases hit 128.1% in 2025, while the deepest fall reached 15.78% in 2025.
  • Over 4 years, Current Leases stood at $966000.0 in 2022, then rose by 24.22% to $1.2 million in 2023, then increased by 18.83% to $1.4 million in 2024, then decreased by 15.78% to $1.2 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $1.2 million, $2.7 million, and $2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.